ABSTRACT
This update, written by authors designated by multiple pediatric endocrinology societies (see List of Participating Societies) from around the globe, concisely addresses topics related to changes in GnRHa usage in children and adolescents over the last decade. Topics related to the use of GnRHa in precocious puberty include diagnostic criteria, globally available formulations, considerations of benefit of treatment, monitoring of therapy, adverse events, and long-term outcome data. Additional sections review use in transgender individuals and other pediatric endocrine related conditions. Although there have been many significant changes in GnRHa usage, there is a definite paucity of evidence-based publications to support them. Therefore, this paper is explicitly not intended to evaluate what is recommended in terms of the best use of GnRHa, based on evidence and expert opinion, but rather to describe how these drugs are used, irrespective of any qualitative evaluation. Thus, this paper should be considered a narrative review on GnRHa utilization in precocious puberty and other clinical situations. These changes are reviewed not only to point out deficiencies in the literature but also to stimulate future studies and publications in this area.
Subject(s)
Gonadotropin-Releasing Hormone/therapeutic use , Puberty, Precocious , Adolescent , Child , Female , Humans , Male , Puberty, Precocious/diagnosis , Puberty, Precocious/drug therapy , Puberty, Precocious/pathology , Puberty, Precocious/physiopathologyABSTRACT
The authors report the first case of Stevens-Johnson syndrome which has occurred in a 45 year old patient treated by Triomune containing névirapine. Triomune is used within the context of the African antiretroviral initiative access. It was a mild form whose evolution was favourable when nevirapine was stopped. The prevalence of this affection should increase with the larger use of nevirapine in our countries and the attention of both prescriber and patient must be requested.
Subject(s)
Anti-HIV Agents/adverse effects , Drug Eruptions/etiology , Nevirapine/adverse effects , Stevens-Johnson Syndrome/chemically induced , Cote d'Ivoire , Humans , Male , Middle AgedABSTRACT
Sib-pair linkage analyses were used to search for linkage to a set of chromosome 19 and 21 marker loci in two sets of families with Alzheimer's disease. The advantage of this technique is that no assumption is made about the mode of inheritance of the disease. Some mild suggestions of linkage were found in early-onset families for a chromosome 21 marker and in a set of late-onset families for a chromosome 19 marker.
Subject(s)
Alzheimer Disease/genetics , Genetic Linkage , Aged , Alzheimer Disease/epidemiology , Boston/epidemiology , Chromosome Aberrations/epidemiology , Chromosome Aberrations/genetics , Chromosome Disorders , Chromosome Mapping , Chromosomes, Human, Pair 19 , Chromosomes, Human, Pair 21 , Genetic Markers , Humans , Middle Aged , North Carolina/epidemiologyABSTRACT
Sib-pair linkage analysis was used to screen a large pedigree, ascertained through four members with hypercholesterolemia, for evidence of linkage between 12 quantitative traits and 15 genetic marker loci. Traits were analyzed on the untransformed, natural log and square root-transformed scales. After adjusting for multiple tests, there is a suggestion of linkage between height and the Kidd blood group on chromosome 18 and between VLDL cholesterol, and possibly triglyceride, and KM on chromosome 2.